-
2026-06-23 22:05
-
2026-06-23 18:00
-
2026-06-23 11:30
-
2026-06-22 22:01
European approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and progress
-
2026-06-22 20:33
SHANGHAI, June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration ("NMPA") today, the New Drug Applicatio
-
2026-06-21 04:44
-
2026-06-21 00:50
-
2026-06-18 09:38
-
2026-06-17 17:15
AMSTERDAM, June 17, 2026 /PRNewswire/ -- Central and Eastern European companies continue to balance cash and credit, with 54% of B2B sales paid at the point of sale and 46% made on credit. Yet the credit side is under strain. Late payments now affect 83% of suppliers with nearly
-
2026-06-16 21:47